Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
Adcomm says Intercept’s rare liver disease drug should not get full approval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory
September 14, 2024